Last mentioned: Feb 26, 2026
Q4 2025 Earnings
Company reports quarterly results and provides updates on quality remediation and 2026 outlook.
Q4 2025 Earnings
Company reports results and provides 2026 guidance, signaling continued remediation efforts.
Projected Restart
Target window for the commercial re-launch of SurgiMend and PriMatrix products.
New CEO Appointment
Mojdeh Poul succeeds Jan De Witte as President and CEO of Integra LifeSciences.
New Leadership
Mojdeh Poul assumes role as CEO to lead the company's quality and operational turnaround.
Boston Plant Recall
Integra initiates voluntary recall of SurgiMend and PriMatrix products due to manufacturing issues.
Boston Recall
Integra initiates voluntary recall of all products manufactured in Boston due to endotoxin concerns.
Integra LifeSciences (IART) shares faced downward pressure following its Q4 2025 earnings call, as management detailed an extended timeline for its Boston facility restart and the ongoing costs of its Quality Excellence Program. While the company provided its first full-year 2026 guidance, investor caution remains high regarding the path to normalized growth and product re-launches.
Integra LifeSciences reported its latest quarterly results, highlighting a period of strategic stabilization and operational remediation. While the company continues to address manufacturing challenges at its Boston facility, the appointment of new leadership and steady performance in its Codman Specialty Surgical segment signal a path toward long-term recovery.
Integra LifeSciences reported Q4 2025 results that failed to meet investor expectations, driven by persistent manufacturing challenges and a slower-than-anticipated recovery in its Tissue Technologies segment. Despite growth in the newly acquired Acclarent business, the company's conservative 2026 guidance has triggered a significant market sell-off.